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Objectives: A close margin of 3 mm results in a high risk for locoregional recurrence, but still is not an
independent factor that helps to guide the use of aggressive postoperative therapies in patients with
resected buccal mucosa carcinoma. This suggests there is a diversity of clinical outcomes in this group of
patients. The present study explores the predictors among this clinically debated group of patients.
Materials and Methods: From 2000 to 2008, 30 resected buccal mucosa carcinoma patients with a close
margin of 3 mm were retrospectively included in this study. All patients were treated with radical
surgery together with postoperative radiotherapy (RT) or chemoradiotherapy (CCRT). Locoregional/local/
regional control, disease-free status, disease-speciﬁc survival and overall survival were the study end
points.
Results: Two factors were observed that were able to predict 5-year locoregional control. These were
a pathological N classiﬁcation (pN0 vs. pN1-2, 71.5% vs. 30.0%, p ¼ 0.044) and a very close margin
(> 1 mm vs. 1 mm, 81.8% vs. 50.7%, p ¼ 0.040). Remarkably, the predicting effect of a very close margin
was well translated into disease-free status (81.8% vs. 47.1%, p ¼ 0.024) and disease-speciﬁc survival
(100% vs. 70.6%, p ¼ 0.037). After multivariate analysis, a very close margin of 1 mm was found to
independently predict a high risk of locoregional recurrence (HR, 9.528; 95% CI, 1.326e18.481; p ¼ 0.025)
and disease failure at any site (HR, 12.778; 95% CI, 1.934e25.217; p ¼ 0.013).
Conclusion: More aggressive postoperative treatments should be considered for resected buccal mucosa
carcinoma patients with a very close margin of 1 mm.
Copyright  2011, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC.
All rights reserved.1. Introduction
Buccal mucosa carcinoma has rapidly increased in incidence,
especially in recent years [1]. Radical surgery with or without
postoperative therapies is the treatment of choice in patients withncology, Buddhist Dalin Tzu
hiayi, Taiwan. Tel.: þ886 5
ddhist Compassion Relief Tzu Chiresectable disease, depending on pathological adverse features at
the time of radical surgery [2]. For example, extracapsular nodal
spread and a positive surgical margin are independent guides with
respect to postoperative chemoradiotherapy (CCRT). Other adverse
features guide postoperative radiotherapy (RT) with or without
chemotherapy and these include classiﬁcation as pT3-4, positive
nodal disease, nodal disease at neck level IV-V, vascular embolism
and peri-neural invasion; however a close margin is not one of
these [2].
A close margin has been reported to predict a high risk of cancer
recurrence in many studies [3e6], despite the fact that a deﬁnitionFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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suggested as a deﬁnition for “a close margin”, according to on-line
oncological guidelines [2,3] and studies in Taiwan [6], respectively.
However, we have previously observed that patients with a margin
of 3 mm demonstrate poor clinical outcomes [5]. However, as
mentioned above, a close margin alone is still not an independent
indicator for guiding postoperative adjuvant therapies [2,7]. Thus,
further stratiﬁcation of these patients seems to be essential and has
been debated clinically.
Based on the above, this study explores the factors that are
able to predict clinical outcome and thus guide appropriate
postoperative treatments in resected buccal mucosa carcinoma
patients with a close margin of 3 mm. Speciﬁcally, locoregional/
local/regional control, disease-free survival, disease-speciﬁc
survival and overall survival were deﬁned as the study end
points.Fig. 1. Patient allocation ﬂowchart. CCRT ¼2. Materials and methods
2.1. The ethic considerations
The procedures followed here were approved by our Institution
Review Board (IRB) and are in accordance with the Helsinki
Declaration of 1975 as revised in 1983.
2.2. Patient allocation and clinical data collection
From August 1, 2000, to December 30, 2008, we retrospectively
collected data from 30 resectable buccal mucosa carcinoma
patients who had a pathological margin of3mmandwere treated
with postoperative RT or CCRT (Fig. 1 and Table 1). Two researchers
doubly reviewed all medical records. Data discrepancies were
resolved by consensus. All 30 patients had no distant metastasis atchemoradiotherapy; RT ¼ radiotherapy.
Table 1
Patient characteristics according to postoperative therapy.
Postoperative
treatment, n (%)
p valuea Total, n (%)
RT alone CCRT
Age (years)
50 7 (43.8) 8 (57.1) 0.715 15 (50.0)
>50 9 (56.3) 6 (42.9) 15 (50.0)
Gender
Female 2 (12.5) 2 (14.3) 0.990 4 (13.3)
Male 14 (87.5) 12 (85.7) 26 (86.7)
ECOG PS b
0e1 10 (62.5) 11 (78.6) 0.440 21 (70.0)
2 6 (37.5) 3 (21.4) 9 (30.0)
Smoking
No 2 (12.5) 4 (28.6) 0.378 6 (20.0)
Yes 14 (87.5) 10 (71.4) 24 (80.0)
Betel nut chewing
No 3 (18.8) 4 (28.6) 0.675 7 (23.3)
Yes 13 (81.3) 10 (71.4) 23 (76.7)
Histology
Well to moderate 15 (93.8) 13 (92.9) 0.990 28 (93.3)
Poor differentiation 1 (6.3) 1 (7.1) 2 (6.7)
Invasion depth (mm)
<10 8 (50.0) 4 (28.6) 0.284 12 (40.0)
10 8 (50.0) 10 (71.4) 18 (60.0)
pT status
pT1-3 16 (100) 4 (28.6) <0.001 20 (66.7)
pT4 0 10 (71.4) 10 (33.3)
pN status
pN0 15 (93.8) 10 (71.4) 0.157 25 (83.3)
pN1-2 1 (6.3) 4 (28.6) 5 (16.7)
Pathology stage
I-III 15 (93.8) 2 (14.3) <0.001 17 (56.7)
IVA/B 1 (6.3) 12 (85.7) 13 (43.4)
Pathological margin (mm)
>1 9 (56.3) 4 (28.6) 0.159 13 (43.3)
1 7 (43.7) 10 (71.4) 17 (56.7)
RT dose (Gy)
66 14 (87.5) 2 (14.3) <0.001 16 (53.3)
>66 2 (12.5) 12 (85.7) 14 (46.7)
Total 16 (100) 14 (100) 30 (100)
CCRT ¼ chemoradiotherapy; ECOG PS ¼ Eastern Cooperative Oncology Group
performance status; Gy ¼ Gray; RT ¼ radiotherapy.
a All p values were estimated using Fisher’s exact test.
b ECOG performance status was recorded by a radiation oncologist at the time of
initial presentation at the RT department.
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pathologists prospectively deﬁned pathological features at the time
of radical surgery using an oral cancer-speciﬁc checklist and the
documented items were audited by another independent pathol-
ogist. Pathological invasion depth was measured in millimeters
with a cut-off point of 10mm [8,9], not the original measurement of
anatomic layers, as previously reported [10,11]. Cancer staging was
deﬁned according to the American Joint Committee on Cancer [12].Fig. 2. Kaplan-Meier estimate of locoregional control according to pathological
margin. * The p value was calculated using the log rank test.2.3. Treatment modality
Radical surgery with curative intent was carried out in all
patients. All radical surgery was conducted to gain a 1e2 cm
surgical margin, depending on the surgeon’s available adjustments
and the individual’s condition. Intra-operatively, routine frozen
sectioning was also performed to conﬁrm margin status. Amongthe 30 patients, 15 individuals received bone resectioning as part of
their primary tumor management, either partial mandibulectomy
(n ¼ 12) or maxillectomy (n ¼ 3). In terms of neck management,
15 patients received supra-omohyoid neck dissection and 12
patients received modiﬁed radical neck dissection. Altogether, 23
patients received ipsilateral neck dissection and four patients
received bilateral neck dissection. All patients received post-
operative RT with or without chemotherapy. Postoperative thera-
pies were started 4e7 weeks after surgery.
Intensity-modulated radiotherapy (IMRT) with inverse planning
system (PLATO, Nucleotron Inc., The Netherlands) was used for
delivering the RT, as previously described [5]. Brieﬂy, the prescribed
doses were as follows: 60e72 Gy to the primary surgical bed;
60e66Gy to thehigh-risknodal station;and50e60Gyto the low-risk
nodal basin. Conventional fractionationwasgiven, i.e.,1.8e2.0Gy/day
and 5 days per week for 6e7 weeks. During the RT course, weekly
electronic portal imaging was performed for veriﬁcation. The dose to
the spinal cord was limited to 45 Gy. The prescribed RT dose for
patients treated with RT alone or with CCRT was similar.
Chemotherapy was used in conjunction with RT, if indicated, as
previously described [5]. Brieﬂy, chemotherapy was indicated in
patients with extracapsular nodal spread or with a combination of
any two minor risk factors, including perineural invasion, vascular
permeation, pT3-4 and positive nodal disease. The chemotherapy
protocol contained a concurrent phase of two-cycle cisplatin single
agent during RT and an adjuvant phase of another two-cycle
cisplatin and ﬂuorouracil (5-FU) after RT. The regimen and doses
were as follows: concurrent phase, cisplatin alone (60e100 mg/m2/
day on Day 1); and adjuvant phase, cisplatin (60e100 mg/m2/day
on Day 1) and 5-FU (1000 mg/m2/day on Days 1e5). The cycle was
repeated for 3 weeks.2.4. Statistical methods and deﬁnitions
Commercial software (SPSS version 12.0; SPSS Inc., Chicago, IL,
USA) was used to conduct the statistical analysis and involved the
following. A Kaplan-Meier analysis was used to estimate survival
and cancer control rates. The log-rank test was used to assess curve
differences between groups. Fisher’s exact test was used to evaluate
differences between categorical variables. Cox proportional hazard
regression was used to perform univariate and multivariate
Table 2
Multivariate analysis for locoregional disease-control end points.
Locoregional controla Local controla Regional controla
HR (95CI) HR (95CI) HR (95CI)
Age (years)
50 1 1 1
>50 4.540 (0.219e19.032), p ¼ 0.328 8.503 (0.274e26.768), p ¼ 0.222 2.432 (0.014e16.968), p ¼ 0.832
Gender
Female 1 1 1
Male 3.592 (0.004e19.849), p ¼ 0.710 9.866 (0.034e29.849), p ¼ 0.316 1.673 (0.083e17.347), p ¼ 0.762
ECOG PS b
0e1 1 1 1
2 1.159 (0.050e16.692), p ¼ 0.927 1.319 (0.319e11.689), p ¼ 0.619 4.622 (0.192e26.193), p ¼ 0.892
Smoking
No 1 1 1
Yes 11.937 (0.567e25.692), p ¼ 0.369 9.198 (0.740e24.082), p ¼ 0.066 2.198 (0.279e18.685), p ¼ 0.866
Betel nut chewing
No 1 1 1
Yes 1.451 (0.061e23.160), p ¼ 0.824 1.770 (0.013e13.960), p ¼ 0.900 0.916 (0.123e15.933), p ¼ 0.831
Histology
Good to moderate 1 1 1
Poor differentiation 7.078 (0.179e19.769), p ¼ 0.419 13.276 (0.560e29.639), p ¼ 0.306 7.472 (0.656e37.662), p ¼ 0.696
Invasion depth (mm)
<10 1 1 1
10 1.790 (0.790e20.980), p ¼ 0.715 2.843 (0.046e17.240), p ¼ 0.620 1.043 (0.234e17.140), p ¼ 0.942
PNI
No 1 1 1
Yes 3.912 (0.409e14.921), p ¼ 0.492 5.932 (0.466e22.925), p ¼ 0.629 4.998 (0.462e18.832), p ¼ 0.590
LVSI
No 1 1 1
Yes 4.983 (0.832e13.984), p ¼ 0.493 3.073 (0.873e15.962), p ¼ 0.783 5.893 (0.872e19.972), p ¼ 0.653
ECS
No 1 1 1
Yes 6.829 (0.473e22.872), p ¼ 0.682 8.962 (0.739e22.982), p ¼ 0.783 9.392 (0.893e29.301), p ¼ 0.198
pT status
pT1-3 1 1 1
pT4 1.686 (0.089e18.768), p ¼ 0.730 3.686 (0.098e19.369), p ¼ 0.557 3.742 (0.291e21.949), p ¼ 0.851
pN status
pN0 1 1 1
pN1-2 3.981 (0.678e13.189), p ¼ 0.109 7.470 (0.426e18.439), p ¼ 0.113 6.81 (0.916e21.431), p ¼ 0.063
Pathology stage
I-III 1 1 1
IVA/B 1.986 (0.036e13.765), p ¼ 0.750 4.631 (0.115e15.239), p ¼ 0.211 2.433 (0.395e19.293), p ¼ 0.764
Pathological margin (mm)
>1 1 1 1
1 9.528 (1.326e18.481), p ¼ 0.025* 14.022 (1.128e29.762), p ¼ 0.043* 3.902 (0.385e11.911), p ¼ 0.672
RT dose (Gy)
66 1 1 1
>66 6.548 (0.504e18.148), p ¼ 0.151 4.649 (0.531e13.042), p ¼ 0.165 7.891 (0.031e19.147), p ¼ 0.763
95CI ¼ 95% conﬁdence interval; CCRT ¼ chemoradiotherapy; ECOG PS ¼ Eastern Cooperative Oncology Group performance status; ECS ¼ extracapsular spreading of nodal
disease; Gy ¼ Gray; HR ¼ hazard ratio; LVSI ¼ lymphvascular space invasion; PNI ¼ peri-neural inﬁltration; RT ¼ radiotherapy.
* p < 0.05.
a All p values were estimated using Cox proportional hazards regression.
b ECOG performance status was recorded by a radiation oncologist at the time of initial presentation at the RT department.
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order to provide a good estimate of effective size, all HRs were
provided with a corresponding 95% conﬁdence interval (95% CI) in
addition to a conventional p value. All tests were two-tailed and
considered to be statistically signiﬁcant when p< 0.05. Only factors
that gained a statistical signiﬁcant trend (p < 0.1) in univariate
analysis were used for multivariate analysis.
All time-to-event analyses calculated the time interval from the
day of pathological diagnosis to the day of the corresponding endevent. The corresponding end events were deﬁned as follows:
locoregional control, the ﬁrst day of local or regional cancer recur-
rence; local control, the ﬁrst day of local recurrence; disease-free
survival, the ﬁrst day of disease failure at any site; disease-speciﬁc
survival, the day of death from cancer; overall survival, the day of
death from any cause; and, the follow-up time, the day of death from
any cause or the day of last follow-up. In addition, all time-to-event
analyses were censored at the day of last follow-up or the day of
non-end-event death.
Fig. 3. Kaplan-Meier estimates of disease-free survival (A) and disease-speciﬁc
survival (B) according to the pathological margin. * The p value was calculated using
the log rank test.
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3.1. Patient, tumor and treatment outcomes
Table 1 shows patient characteristics according to postoperative
treatment modality in terms of factors related to the patient, tumor
and treatment domains. There were 26 male and four female
patients, with amedian age of 51.5 years (range, 35e82 years). Most
patients had pN0 disease (83.3%, 25/30). All patients had R0
resectioning with a nearest surgical margin of > 0 mm but 3 mm
(Fig. 1).
The 5-year control and survival rates for all 30 buccal cancer
patients who had a close margin of 3 mm were as follows: local
control, 67.2%; regional (neck) control, 93.1%; locoregional control,
64.8%; distant metastasis control, 93.1%; disease-free survival,
62.4%; disease-speciﬁc survival, 83.3%; and overall survival, 83.3%.
The median duration of follow-up for the patients was 52.8 months
(mean, 56.8 months; standard deviation, 11.5 months; and, range,
6.4e65.8 months). At the time of analysis, six patients (20%, 6/30)
had died and 10 patients (33.3%,10/30) had locoregional recurrence
(Fig. 1). Salvage therapy was performed on eight individuals (80%,
8/10). Among those who underwent salvage therapy, six (75%, 6/8)
were still alive and two (25%, 2/8) were dead at the time of the
analysis.
3.2. The predictors that are correlated with treatment outcomes
Two major predictors for 5-year locoregional control were
detected: a pathological margin (> 1 mm vs. 1 mm; 81.8% vs.
50.7%, p ¼ 0.040; Fig. 2) and pathological N classiﬁcation (pN0 vs.
pN1-2; 71.5% vs. 30.0%, p ¼ 0.044). After multivariate analysis, only
a very close margin (1 mm) was an independent predictor for
high-risk locoregional failure (HR, 9.528; 95% CI, 1.326e18.481;
p ¼ 0.025; Table 2).
The 5-year locoregional control rates according to pathological
stage and treatment factors were as follows: pathological T classi-
ﬁcation (pT1-3 vs. pT4, 69.6% vs. 54.0%, p ¼ 0.553), overall patho-
logical stage (I-III vs. IVA/B, 76.0% vs. 49.9%, p ¼ 0.123),
extracapsular spreading of nodal disease (no vs. yes, 71.5% vs. 30.0%,
p¼ 0.044), perineural invasion (no vs. yes, 80% vs. 61.7%, p¼ 0.446),
postoperative therapy (RTalone vs. CCRT, 74.5% vs. 53.4%, p¼ 0.246)
and RT dose (66 Gy vs. > 66 Gy, 81.3% vs. 42.7%, p ¼ 0.059).
Furthermore, the effect of surgical margin was well translated into
disease-free and disease-speciﬁc survival (Fig. 3). After multivariate
analysis, a very close margin was also the only independent
predictor for a high risk of disease failure at any site (HR, 12.778;
95% CI, 1.934e25.217; p ¼ 0.013; Table 3). All time-to-event end
points are reported according to their predictive factors in Table 4
and Table 5.
4. Discussion
In the present study, we observed that a very close margin
(1 mm) was the most important outcome predictor in resectable
buccal mucosa carcinoma patients with a close margin 3 mm in
terms of 5-year locoregional control (Fig. 2, Table 2 and Table 4),
disease-free survival and disease-speciﬁc survival (Fig. 3, Table 3
and Table 5). Thus, in clinical practice, it is reasonable to treat
these patients with aggressive modalities, such as re-resectioning
to gain a wider margin or intensive CCRT after surgery, which is
similar to the treatment of patients who have a positive margin
(0 mm).
Buccal mucosa carcinoma has been observed to have poorer
clinical outcomes than carcinoma arising from other sites in the
oral cavity [13]. A high recurrence rate has been reported even inearly-stage patients and rates as high as 40e80%when treatedwith
wide excision alone have been published [14,15]. However, in Tai-
wan, a much better treatment outcome has been observed, with
a recurrence rate of less than 20% [6]. This discrepancy in treatment
outcomes may be because of different proportions of close-margin
patients; i.e., surgery in Taiwan is more radical with fewer close-
margin patients, which will have an obvious beneﬁt (around 10%
in 4 mm in a Taiwan series) [6]. Our results indicate that patients
with very close margin have poorer outcomes and this supports the
role of radical surgery with adequate margin.
Other than a very close margin, pathological T status has
previously been observed to be a potential predictor for patient
survival among patients with a free margin [16]. However, our
results did not support this ﬁnding. On the other hand, we observed
that pathology N status seems to be correlated with locoregional
control and disease-free survival (pN0 vs. pN1-2, 71.5% vs. 30.0%,
p ¼ 0.044; Table 4 and Table 5). However, after multivariate anal-
ysis, this observation was found not to be statistically signiﬁcant
(Table 2 and Table 3).
Table 3
Multivariate analysis for the patient survival end points.
Disease-free survivala Disease-speciﬁc survivala Overall survivala
HR (95CI) HR (95CI) HR (95CI)
Age (years)
50 1 1 1
>50 4.088 (0.189e18.388), p ¼ 0.369 3.280 (0.498e16.488), p ¼ 0.193 4.8037 (0.298e12.988), p ¼ 0.239
Gender
Female 1 1 1
Male 4.326 (0.140e16.018), p ¼ 0.369 1.54 (0.297e11.918), p ¼ 0.698 4.995 (0.293e9.832), p ¼ 0.492
ECOG PSb
0e1 1 1 1
2 1.266 (0.155e12.189), p ¼ 0.886 4.826 (0.355e14.935), p ¼ 0.386 4.998 (0.192e9.921), p ¼ 0.492
Smoking
No 1 1 1
Yes 9.960 (0.175e17.517), p ¼ 0.341 12.446 (0.475e29.419), p ¼ 0.134 11.246 (0.282e25.835), p ¼ 0.739
Betel nut chewing
No 1 1 1
Yes 1.699 (0.169e12.065), p ¼ 0.746 0.632 (0.087e5.845), p ¼ 0.396 0.51 (0.089e7.925), p ¼ 0.742
Histology
Well to moderate 1 1 1
Good differentiation 8.168 (0.178e21.695), p ¼ 0.328 5.103 (0.098e18.592), p ¼ 0.218 8.024 (0.098e19.815), p ¼ 0.892
Invasion depth (mm)
<10 1 1 1
10 3.818 (0.116e15.135), p ¼ 0.452 5.899 (0.234e18.593), p ¼ 0.782 8.921 (0.493e18.982), p ¼ 0.873
PNI
No 1 1 1
Yes 5.302 (0.509e18.943), p ¼ 0.654 8.981 (0.492e19.734), p ¼ 0.619 6.932 (0.539e19.819), p ¼ 0.621
LVSI
No 1 1 1
Yes 5.342 (0.593e14.783), p ¼ 0.592 6.392 (0.204e14.763), p ¼ 0.592 4.732 (0.529e13.890), p ¼ 0.593
ECS
No 1 1 1
Yes 9.872 (0.498e24.981), p ¼ 0.194 14.902 (0.245e33.981), p ¼ 0.298 11.734 (0.892e29.124), p ¼ 0.392
pT status
pT1-3 1 1 1
pT4 1.166 (0.178 e 8.645), p ¼ 0.914 1.239 (0.281 e 8.388), p ¼ 0.872 2.926 (0.878 e 5.743), p ¼ 0.192
pN status
pN0 1 1 1
pN1-2 7.984 (0.778e18.587), p ¼ 0.094 11.83 (0.379e28.849), p ¼ 0.170 9.382 (0.822e25.793), p ¼ 0.112
Pathology stage
I-III 1 1 1
IVA/B 2.655 (0.158e12.762), p ¼ 0.616 1.950 (0.745e9.837), p ¼ 0.136 1.325 (0.086e7.965), p ¼ 0.671
Pathological margin (mm)
>1 1 1 1
1 12.778 (1.934e25.217), p ¼ 0.013* 16.521 (0.882e36.462), p ¼ 0.198 15.879 (0.538e35.979), p ¼ 0.879
RT dose (Gy)
66 1 1 1
>66 5.648 (0.412e12.158), p ¼ 0.198 5.541 (0.148e14.982), p ¼ 0.779 4.958 (0.212e16.192), p ¼ 0.698
95CI ¼ 95% conﬁdence interval; CCRT ¼ chemoradiotherapy; ECOG PS ¼ Eastern Cooperative Oncology Group performance status; ECS ¼ extracapsular spreading of nodal
disease; Gy ¼ Gray; HR ¼ hazard ratio; LVSI ¼ lymphvascular space invasion; PNI ¼ peri-neural inﬁltration; RT ¼ radiotherapy.
* p < 0.05.
a All p values were estimated using Cox proportional hazards regression.
b ECOG performance status was recorded by a radiation oncologist at the time of initial presentation at the RT department.
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result in a close margin, such as post-formalin-ﬁxed tissue
shrinkage, the anatomic limitations and the intrinsically biological
aggressiveness of cancer itself [17]. In the third situation, more
biological aggressiveness results in a higher cancer cell inﬁltration
rate and thus an unexpectedly close surgical margin after curative-
intent radical surgery. Therefore, in addition to physical reasons,
intrinsically biological aggressiveness may partly be involved in
increasing postoperative disease failure [17]. The fact that ourresults indicated that a very close margin (1 mm) had a higher
disease failure supports this biological hypothesis in part at least.
As mentioned above, a close margin may, at least in part,
represent the degree of intrinsic cancer aggressiveness, rather than
a purely physical problem [17,18]. Thus, despite carefully surgical
planning and manipulation, close margins cannot be totally avoi-
ded; there is a reported rate of around 10% in Taiwan [6]. In the
literature, a close margin has been reported to be linked to a poor
treatment outcome [3,5]. However, up to the present study, a close
Table 4
Kaplan-Meier analysis for 5-year locoregional disease-control end points.
Locoregional controla Local controla Regional controla
Age (years)
50 vs. >50 67.5% vs. 60.0%, p ¼ 0.362 67.5% vs. 65.0%, p ¼ 0.547 85.7% vs. 100%, p ¼ 0.136
Gender
Female vs. male 67.5% vs. 50.0%, p ¼ 0.335 70.3% vs. 50.0%, p ¼ 0.233 96.0% vs. 75.0%, p ¼ 0.143
ECOG PSb
0e1 vs. 2 63.1% vs. 66.7%, p ¼ 0.903 63.1% vs. 76.2%, p ¼ 0.670 95.2% vs. 87.5%, p ¼ 0.446
Smoking
No vs. yes 68.9% vs. 50.0%, p ¼ 0.192 71.9% vs. 50.0%, p ¼ 0.120 95.8% vs. 80.0%, p ¼ 0.228
Betel nut chewing
No vs. yes 57.1% vs. 66.9%, p ¼ 0.544 57.1% vs. 70.0%, p ¼ 0.398 85.7% vs. 95.5%, p ¼ 0.403
Invasion depth (mm)
<10 vs. 10 83.3% vs. 60.3%, p ¼ 0.335 83.3% vs. 63.2%, p ¼ 0.399 100% vs. 91.3%, p ¼ 0.465
pT status
pT1-3 vs. pT4 69.6% vs. 54.0%, p ¼ 0.553 73.5% vs. 54.0%, p ¼ 0.375 94.7% vs. 90.0%, p ¼ 0.659
pN status
pN0 vs. pN1-2 71.5% vs. 30.0%, p ¼ 0.044* 71.5% vs. 40.0%, p ¼ 0.250 96.0% vs. 75.0%, p ¼ 0.103
Pathology stage
I-III vs. IVA/B 76.0 vs. 49.9%, p ¼ 0.123 76.0 vs. 54.8%, p ¼ 0.227 100% vs. 83.3%, p ¼ 0.085
Pathological margin (mm)
>1 vs. 1 81.8% vs. 50.7%, p ¼ 0.040* 81.8% vs. 54.3%, p ¼ 0.063 100% vs. 87.5%, p ¼ 0.195
RT dose (Gy)
66 vs. >66 81.3% vs. 42.7%, p ¼ 0.059 86.7% vs. 42.7%, p ¼ 0.051 93.8% vs. 92.3%, p ¼ 0.901
* p < 0.05.
ECOG PS ¼ Eastern Cooperative Oncology Group performance status; Gy ¼ Gray; RT ¼ radiotherapy.
a All p values were estimated using the log rank test.
b ECOG performance status was recorded by a radiation oncologist at the time of initial presentation at the RT department.
Table 5
Kaplan-Meier analysis for 5-year patient survival end points.
Disease-free survivala Disease-speciﬁc survivala Overall survivala
Age (years)
50 vs. >50 63.0% vs. 60.0%, p ¼ 0.564 93.3% vs. 73.3%, p ¼ 0.159 93.3% vs. 73.3%, p ¼ 0.116
Gender
Female vs. male 64.7% vs. 50.0%, p ¼ 0.446 84.6% vs. 75.0%, p ¼ 0.673 84.6% vs. 75.0%, p ¼ 0.673
ECOG PSb
0e1 vs. 2 66.7% vs. 59.9%, p ¼ 0.954 90.5% vs. 66.7%, p ¼ 0.108 90.5% vs. 66.7%, p ¼ 0.079
Smoking
No vs. yes 65.9% vs. 50.0%, p ¼ 0.280 87.5% vs. 66.7%, p ¼ 0.194 87.5% vs. 66.7%, p ¼ 0.194
Betel nut chewing
No vs. yes 57.1% vs. 63.7%, p ¼ 0.698 71.4% vs. 84.0%, p ¼ 0.413 71.4% vs. 87.0%, p ¼ 0.672
Invasion depth (mm)
<10 vs. 10 83.3% vs. 57.4%, p ¼ 0.281 100% vs. 79.2%, p ¼ 0.242 100% vs. 79.2%, p ¼ 0.092
pT status
pT1-3 vs. pT4 69.6% vs. 48.0%, p ¼ 0.318 85.0% vs. 80.0%, p ¼ 0.732 85.0% vs. 80.0%, p ¼ 0.982
pN status
pN0 vs. pN1-2 71.5% vs. 30.0%, p ¼ 0.044* 92.0% vs. 68.0%, p ¼ 0.101 92.0% vs. 68.0%, p ¼ 0.101
Pathology stage
I-III vs. IVA/B 76.0 vs. 44.9%, p ¼ 0.062 94.0 vs. 69.2%, p ¼ 0.061 94.1 vs. 69.2%, p ¼ 0.150
Pathological margin (mm)
>1 vs. 1 81.8% vs. 47.1%, p ¼ 0.024* 100% vs. 70.6%, p ¼ 0.037* 94.1% vs. 70.6%, p ¼ 0.099
RT dose (Gy)
66 vs. >66 81.3% vs. 39.2%, p ¼ 0.052 93.8% vs. 71.4%, p ¼ 0.107 93.8% vs. 71.4%, p ¼ 0.227
* p < 0.05.
ECOG PS ¼ Eastern Cooperative Oncology Group performance status; Gy ¼ Gray; RT ¼ radiotherapy.
a All p values were estimated using the log rank test.
b ECOG performance status was recorded by a radiation oncologist at the time of initial presentation at the RT department.
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independently guided postoperative therapies [2]. Nonetheless,
these patients comprise a unique study population that demon-
strates a clinically debating and biologically interesting proﬁle.
Further studies focusing on this study population should be
considered, especially attempts to explore the underlying biological
mechanism. In such circumstances, developing a biopredictor that
involves a very close margin is a reasonable next step in order to
further stratify these patients. In consideration of this, an
epigenetic-based biopredictor has been reported to be a potential
candidate for further investigation [19].
The important features of this study are as follows. Firstly, all
pathology features were prospectively deﬁned at the time of radical
surgery using an oral cancer-speciﬁc pathological checklist.
Secondly, the documented pathological report was denoted by
a pathologist and then audited in-house by another independent
pathologist. Finally andmost importantly, the study populationwas
relatively pure in terms of resectable buccal mucosa carcinoma
patients who had a close margin of 3 mm. This study population
was constructed speciﬁcally as a clinical population that should
allow investigation in this area using current evidence-based
treatment guidelines [2].
Twomain limitations of this study are obvious. Firstly, the study
design is retrospective. Thus, selection bias inevitably exits and
cannot be fully adjusted for, even after time-to-event-speciﬁc
multivariate analysis such as Cox proportional hazard regression
[20,21]. Secondly, a relatively small number of cases was included,
although the positive factor of these being a relatively unique study
population remains valid. Therefore, a further prospective study
with a larger sample size is needed to conﬁrm our results. None-
theless, the ﬁndings of the present study shed light on how to
aggressively treat patients with a very close margin and are worthy
of serious consideration. In summary, we observed that a very close
margin of 1 mm seems to be the most important factor when
predicting treatment outcomes in resectable buccal mucosa carci-
noma patients with a free but close margin of 3 mm.References
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